CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer

Neoplasma

Volumn 57, Issue 4, 2010, Pages 325-332

  Plevova, P ^a,b   Cerna, D ^a   Balcar, A ^a   Foretova, L ^c   Zapletalova, J ^b   Silhanova, E ^a   Curik, R ^d   Dvorackova, J ^d  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d Faculty Hospital Ostrava   (Czech Republic)

Author keywords

BRCA1 gene; BRCA2 gene; Breast cancer; CCND1 gene amplification; Fluorescence in situ hybridization; ZNF217 gene amplification

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 217; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; HER2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADULT; BREAST TUMOR; COLLOID CARCINOMA; ENZYME IMMUNOASSAY; GENETIC PREDISPOSITION; GENETICS; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANS-ACTIVATORS; YOUNG ADULT;

EID: 77955284204     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_04_325     Document Type: Article

References (47)

1. AL-KURAYA K, SCHRAML P, TORHORST J, TAPIA C, ZAHARIEVA B et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64: 8534-8540. doi:10.1158/0008-5472.CAN-04-1945
2. GINESTIER C, CERVERA N, FINETTI P, ESTEYRIES S, ESTERNI B et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 2006; 12: 4533-4544. doi:10.1158/1078-0432.CCR-05-2339
3. HODGSON JG, CHIN K, COLLINS C, GRAY JW Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 2003; 78: 337-345. doi:10.1023/A:1023085825042
4. TANNER MM, TIRKKONEN M, KALLIONIEMI A, HOLLI K, COLLINS C et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995; 1: 1455-1461.
5. RAHMAN A, STRATTON MR The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121. doi:10.1146/ annurev.genet.32.1.95
6. ATCHLEY DP, ALBARRACIN CT, LOPEZ A, VALERO V, AMOS CI et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282-4288. doi:10.1200/ JCO.2008.16.6231
7. HONRADO E, BENÍTEZ J, PALACIOS J The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005; 18: 1305-1320. doi:10.1038/modpathol.3800453
8. BANE AL, BECK JC, BLEIWEISS I, BUYS SS, CATALANO E et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007; 31: 121-128. doi:10.1097/01.pas.0000213351.49767.0f
9. GRUSHKO TA, BLACKWOOD AM, SCHUMM PL, HAGOS FG, ADEYANJU MO et al. Molecular-Cytogenetic Analysis of HER-2/neu Gene in BRCA1-associated Breast Cancers. Cancer Research 2002; 62: 1481-1488.
10. LAKHANI SRR, VAN DE VIJVER MJ, JACQUEMIER J, ANDERSON TJ, OSIN PP et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318. doi:10.1200/JCO.2002.09.023
11. PLEVOVA P, BOUCHAL J, FIURASKOVA M, FORETOVA L, NAVRATILOVA M et al. PML protein expression in hereditary and sporadic breast cancer. Neoplasma 2007; 54: 263-268.
12. TOMMISKA J, BARTKOVA J, HEINONEN M, HAUTALA L, KILPIVAARA O et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008; 27; 2501-2506. doi:10.1038/sj.onc.1210885
13. JOHANNSSON OT, IDVALL I, ANDERSON C, BORG A, BARKARDOTTIR RB et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362-371. doi:10.1016/S0959-8049(97)89007-7
14. ARMES JE, TRUTE L, WHITE D, SOUTHEY MC, HAMMET F et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-2017.
15. ROBSON M, RAJAN P, ROSEN PP, GILEWSKI T, HIRSCHAUT Y et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998; 58: 1839-1842.
16. VAZIRI SA, TUBBS RR, DARLINGTON G, CASEY G Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 2001; 54: 259-263. doi:10.1136/mp.54.4.259
17. PALACIOS J, HONRADO E, OSORIO A, CAZORLA A, SARRIO D et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005; 90: 5-14. doi:10.1007/s10549-004-1536-0
18. SOBIN LH, editor. International Union Against Cancer (UICC): TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002.
19. GOLDSTEIN NS, ARMIN M Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Commitee on cancer stage IV colon adenocarcinoma. Implications for a standardized scoring system. Cancer 2001; 92: 1331-1346. doi:10.1002/1097-0142(20010901)92:5<1331:: AID-CNCR1455>3.0.CO;2-M
20. RENNSTAM K, BALDETORP B, KYTÖLÄ S, TANNER M, ISOLA J Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001; 61: 1214-1219.
21. SIMPSON JF, QUAN DE, O'MALLEY F, ODOM-MARYON T, CLARKE PE Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997; 151: 161-168.
22. ELSHEIKH S, GREEN AR, ALESKANDARANY MA, GRAINGE M, PAISH CE et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2007; 109: 325-335. doi:10.1007/s10549-007-9659-8
23. LETESSIER A, SIRCOULOMB F, GINESTIER C, CERVERA N, MONVILLE F et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11p13, 12p13, 17p12, and 20q13 amplifications in breast cancers. BMC Cancer 2006; 6: 245-257. doi:10.1186/1471-2407-6-245
24. AALTONEN K, BLOMQVIST C, AMINI RM, EEROLA H, AITTOMAÄKI K et al. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 2008; 14: 1976-1983. doi:10.1158/1078-0432. CCR-07-4100
25. COLOMBO M, GIAROLA M, MARIANI L, RIPAMONTI CB, DE BENEDETTI V et al. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Mod Pathol 2008; 21: 1262-1270. doi:10.1038/modpathol.2008.43
26. OSIN P, GUSTERSON BA, PHILP E, WALTER J, BARTEK J et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998; 34: 1683-1686. doi:10.1016/S0959-8049(98)00248-2
27. PINES J Cyclins: wheels within wheels. Cell Frowth Differ 1991; 2: 305-310.
28. SUTHERLAND RL, WATTS CKW, MUSGROVE EA Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J Steroid Biochm Mol Biol 1993; 47: 1-6. doi:10.1016/0960-0760(93)90062-2
29. FANTL V, RICHARDS MA, SMITH R, LAMMIE GA, JOHNSTONE G et al. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 1990; 26: 423-429. doi:10.1016/0277-5379(90)90009-I
30. LAMMIE GA, FANTL V, SMITH RJ, LAMMIE GGA, JOHNSTONE G et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439-444.
31. SICINSKI P, DONAHER JL, PARKER SB, LI T, FAZELI A et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82: 621-630. doi:10.1016/0092-8674(95)90034-9
32. WANG TC, CARDIFF RD, ZUKERBERG L, LEES E, ARNOLD A et al. Mammary hyperplasia and carcinoma in MMTC-cyclin D1 transgenic mice. Nature 1994; 369: 669-671. doi:10.1038/369669a0
33. HAO L, ELSHAMY WM BRCA_IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. Ing J Cancer 2007; 121: 39-46. doi:10.1002/ijc.22597
34. NAKUCI E, MAHNER S, DIRENZO J, ELSHAMY WM BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res 2006; 312: 3120-3131. doi:10.1016/ j.yexcr.2006.06.021
35. FRECH MS, TORRE KM, ROBINSON GW, FURTH PA Loss of cyclin D1 in concert with deregulated estrogen receptor (expression induces DNA damage response activation and interrupts mammary gland morhogenesis. Oncogene 2008; 27: 3186-3193. doi:10.1038/sj.onc.1210974
36. DE BOCK GH, TOLLENAAR RA, PAPELARD H, CORNELISSE CJ, DEVILEE P et al. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 2001; 85: 1347-1350. doi:10.1054/bjoc.2001.2103
37. BOSTNER J, AHNSTRÖM WALTERSSON N, FORNANDER T, SKOOG L, NORDENSKJÖLD B et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007; 26: 6997-7005. doi:10.1038/sj.onc.1210506
38. COLLINS C, ROMMENS JM, KOWBEL D, GODFREY T, TANNER M et al. Positional cloning of ZNF217 and NABC1: Genes amplifie at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998; 95: 8703-8708. doi:10.1073/pnas.95.15.8703
39. NONET GH, STAMPFER MR, CHIN K, GRAY JW, COLLINS CC et al. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001; 61: 1250-1254.
40. SHIMADA M, IMURA J, KOZAKI T, FUJIMORI T, ASAKAWA S, et al. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Oncology Reports 2005; 13: 633-641.
41. GANCBERG D, LESPAGNARD L, ROUAS G, PAESMANS M, PICCART M et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000; 113: 675-682.
42. DENG CX, BRODIE SG Roles of BRCA1 and its interacting proteins. Bioessays 2000; 22: 728-737. doi:10.1002/1521-1878(200008)22:8<728::AID-BIES6>3.0.CO;2-B
43. IRMINGER-FINGER I, SIEGEL BD, LEUNG WC The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins. Biol Chem 1999; 380: 117-128. doi:10.1515/BC.1999.019
44. STARK GR Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 1993; 61: 87-113. doi:10.1016/ S0065-230X(08)60956-2
45. PARK PC, DE BONI U A specific conformation of the territory of chromosome 17 locates ERBB-2 sequences to a DNase-hypersensitive domain at the nuclear periphery. Chromosoma 1998; 107: 87-95. doi:10.1007/s004120050284
46. STARK GR, DEBATISSE M, GIULOTTO E, WAHL GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 1989; 57: 901-908. doi:10.1016/0092-8674(89)90328-0
47. TRASK BJ, HAMLIN JL. Early dihydrofolate reductase gene amplification events in CHO cells usually occur on the same chromosome arm as the original locus. Genes Dev 1989; 3: 1913-1925. doi:10.1101/gad.3.12a.1913